Penn Medicine Provider
Infectious Diseases
Pablo Tebas, MD
4.9
(107)
Accepting new patients
Sees patients age 18 and up
MacGregor Infection Medicine and Travel Program

About me

  • Director, Developmental Core, Penn Center for AIDS Research
  • Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
  • Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Universidad Autonoma De Madrid
  • Residency: Barnes-Jewish Hospital - Washington University, St. Louis

What my patients think about me

Average Rating
4.9

107 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
he cares
April 2025
5.0
5.0
answer your what's and why's
April 2025
5.0
5.0
doctor is very good n very respectful
March 2025
5.0
5.0
the care i receive from dr tebas is wonderful. there's no rushing and he's very considerate and caring.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Tebas is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Moskovljevic, M., Dragoni, F., Board, N. L., Wu, F., Lai, J., Zhang, H., White, J. R., Hoh, R., Lynn, K., Tebas, P., Mounzer, K., Deeks, S. G., Montaner, L. J., Siliciano, J. D., Siliciano, R. F., Simonetti, F. R. Cognate antigen engagement induces HIV-1 expression in latently infected CD4(+) T cells from people on long-term antiretroviral therapy , Immunity: 2024


Gulick, R. M., Pau, A. K., Daar, E., Evans, L., Gandhi, R. T., Tebas, P., Ridzon, R., Masur, H., Lane, H. C., Nih Covid- Treatment Guidelines Panel, Adimora, A. A., Baker, J., Kreuziger, L. B., Bedimo, R., Belperio, P., Bhalla, A., Burgess, T., Campbell, D., Cantrill, S., Chew, K., Chiotos, K., Coopersmith, C., Davey, R., Dzierba, A., Eisnor, D., Eschenauer, G., Francis, J., Gallagher, J., Glidden, D., Goldenberg, N., Grund, B., Han, A., Hardy, E., Harrison, C., Henderson, L., Higgs, E., Hinkson, C., Hughes, B., Johnson, S., Keller, M., Kim, A., Knight, R., Kuriakose, S., Lennox, J., Lerner, A., Levy, M., Li, J., MacBrayne, C., Martin, G., Nadig, N., Nason, M., Patel, P., Pavia, A., Proschan, M., Schulert, G., Seam, N., Sheikh, V., Simpson, S., Singh, K., Swindells, S., Tien, P., Uyeki, T., Waghmare, A., Wolfe, C., Yazdany, J., Aberg, J. National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned , Ann Intern Med, 177(11): 2024,1547-1557


Pahus, M. H., Zheng, Y., Olefsky, M., Gunst, J. D., Tebas, P., Taiwo, B., Sogaard, O. S., Peluso, M. J., Lie, Y., Reeves, J. D., Petropoulos, C. J., Caskey, M., Bar, K. J. Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies , J Infect Dis: 2024


Bhimraj, A., Falck-Ytter, Y., Kim, A. Y., Li, J. Z., Baden, L. R., Johnson, S., Shafer, R. W., Shoham, S., Tebas, P., Bedimo, R., Cheng, V. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Martin, G. S., MacBrayne, C., Nadig, N., Nakamura, M. M., Shumaker, A. H., Tien, P., Loveless, J., Morgan, R. L., Gandhi, R. T. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis , Clin Infect Dis: 2024


Papasavvas, E., Lu, L., Fair, M., Oliva, I., Cassel, J., Majumdar, S., Mounzer, K., Kostman, J. R., Tebas, P., Bar-Or, A., Muthumani, K., Montaner, L. J. Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-alpha and Anti-IFN-beta Antibodies , J Immunol, 213(6): 2024,808-822


Lee, M. J., Eason, M., Castagna, A., Laura, G., De Scheerder, M. A., Riley, J., Tebas, P., Gunst, J., Sogaard, O., Florence, E., Kroon, E., De Souza, M., Mothe, B., Caskey, M., Fidler, S. The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis , J Int AIDS Soc, 27(8): 2024,e26349


Hamilton, K. W., Hua, E., Dutcher, L., Fernandez Lynch, H., Junker, P., Doucette, A. G., Werner, D., Kannel, E. Z., Civitello, T., Gabriel, P., Ahya, V. N., Jacobs, D. A., Garfall, A., Pratz, K., Degnan, K. O., Blumberg, E. A., Capozzi, D., Craig, E., Takach, P., Payne, A. S., Geara, A., Koenig, H., Holzman, L., Tebas, P. Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center , Open Forum Infect Dis, 11(8): 2024,ofae388


Molina, J. M., Rizzardini, G., Orrell, C., Afani, A., Calmy, A., Oka, S., Hinestrosa, F., Kumar, P., Tebas, P., Walmsley, S., Grandhi, A., Klopfer, S., Gendrano, I., Eves, K., Correll, T. A., Fox, M. C., Kim, J. Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial , Lancet HIV, 11(6): 2024,e369-e379


Jacobson, J. M., Felber, B. K., Chen, H., Pavlakis, G. N., Mullins, J. I., De Rosa, S. C., Kuritzkes, D. R., Tomaras, G. D., Kinslow, J., Bao, Y., Olefsky, M., Rosati, M., Bear, J., Heptinstall, J. R., Zhang, L., Sawant, S., Hannaman, D., Laird, G. M., Cyktor, J. C., Heath, S. L., Collier, A. C., Koletar, S. L., Taiwo, B. O., Tebas, P., Wohl, D. A., Belaunzaran-Zamudio, P. F., McElrath, M. J., Landay, A. L., Actg Study Team The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy , AIDS, 38(7): 2024,963-973


Papasavvas, E., Lu, L., Fair, M., Oliva, I., Cassel, J., Majumdar, S., Mounzer, K., Kostman, J. R., Tebas, P., Bar-Or, A., Muthumani, K., Montaner, L. J. Cloning and functional characterization of novel human neutralizing anti-interferon-alpha and anti-interferon-beta antibodies , bioRxiv: 2024